Issue Information

Issue Information
Publicado: (2024)

Issue Information
Publicado: (2024)

Issue Information
Publicado: (2024)

Hybrid closed‐loop therapy significantly improved maternal glucose control during pregnancy complicated by type 1 diabetes
por: Iskandar Idris
Publicado: (2024)

The glucagon like peptide‐1 linked to nonarteritic anterior ischemic optic neuropathy
por: Iskandar Idris
Publicado: (2024)

Potential role of glucagon like peptide (GLP)‐1 receptor agonist to reduce risk of colorectal cancer?
por: Iskandar Idris
Publicado: (2024)

Tirzepatide shown to be effective at reducing sleep disturbances in patients with obstructive sleep apnoea
por: Iskandar Idris
Publicado: (2024)

Can diet and exercise intervention prevent type 2 diabetes in individuals with a high genetic risk?
por: Iskandar Idris
Publicado: (2024)

Appropriate timing of exercise for adults with obesity including those with type 2 diabetes
por: Iskandar Idris
Publicado: (2024)

Extension study from DIRECT showed ongoing remission rate from type 2 diabetes in some patient following very low calorie diet at 5 years
por: Iskandar Idris
Publicado: (2024)

Adults who are overweight or obese may experience greater pain intensity compared with normal weight individuals?
por: Iskandar Idris
Publicado: (2024)

Tirzepatide shown to improve clinical outcomes for patients with heart failure with preserved ejection fraction (HFpEF) and obesity
por: Iskandar Idris
Publicado: (2024)

Glucagon like peptide‐1 (GLP‐1) therapy is associated with reduced risk of developing cirrhosis and liver cancer in people with type 2 diabetes with chronic liver disease
por: Iskandar Idris
Publicado: (2024)

The US Food and Drug administration has approved resmetirom as the first drug to treat metabolic dysfunction‐associated steatohepatitis (MASH)
por: Iskandar Idris
Publicado: (2024)

Potential new therapies to preserve lean muscle mass loss when used in combination with glucagon‐like peptide 1 (GLP‐1) receptor agonist being studied
por: Iskandar Idris
Publicado: (2024)

Epigenetic changes shown to cause type 2 diabetes
por: Iskandar Idris
Publicado: (2024)

Real world study provided reassurance of the safety of GLP‐1 therapy on mental health and suicide risk
por: Iskandar Idris
Publicado: (2024)

Precision medicine approach to detect obese people who are at high risk of developing diabetes
por: Iskandar Idris
Publicado: (2024)

Real world data showed that the dual GLP gip agonist, Tirzepatide is associated with lower mortality, cardiovascular events and adverse kidney events compared with GLP‐1 analogue
por: Iskandar Idris
Publicado: (2024)

Increased expression of the protein Kallistatin after weight loss induces beneficial metabolic effects: A potential new therapeutic target?
por: Iskandar Idris
Publicado: (2024)

Increasing excess to weight loss injection shown to save thousands of lives a year
por: Iskandar Idris
Publicado: (2024)

Fenofibrate shown to reduce progression of diabetic retinopathy
por: Iskandar Idris
Publicado: (2024)

Issue Information
Publicado: (2024)

Issue Information
Publicado: (2024)

Issue Information
Publicado: (2024)

Issue Information
Publicado: (2024)

Issue Information
Publicado: (2024)

Issue Information
Publicado: (2025)

Issue Information
Publicado: (2025)

Issue Information
Publicado: (2025)

Issue Information
Publicado: (2025)

Issue Information
Publicado: (2025)

Issue Information
Publicado: (2025)

Issue Information
Publicado: (2025)

Issue Information
Publicado: (2026)

Issue Information
Publicado: (2025)